Track 3 Session Descriptions
Socially and Economically Disadvantaged (SDB) and Women-Owned Small Businesses (WOSB) (Stephanie Fertig)
The workshop description, participant bios, and photos to come.
Most public health centers are located in major urban areas, where the majority of the population lives. Though fewer people live in rural areas, rural America covers a much greater geographic area. Services for those in remote locations are typically less accessible, and this limits availability to a variety of health services and products can be detrimental for those in need. Leveraging technological tools, SBIR/STTR-developed products and services may serve rural communities well and present unique opportunities for local small businesses to enhance medical care appreciably. At a minimum, the use of technology should enhance access to services and perhaps facilitate communication between patients/consumers and heath care and other service providers. In this session, current SBIR grantees will discuss tools they have developed or that are under development to serve rural areas. Speakers in this session will be NIH program staff and current and past SBIR companies.
There is a significant challenge for basic scientists to move their discoveries into commercial products. Dr. Flynn will discuss his experience in successfully commercializing his basic discoveries in magnetism into new health care technologies.
The path from discovery to commercialization can be facilitated by using the SBIR mechanism. Dr. Sommer will discuss how his research at Sandia National Laboratories led to new technologies for inexpensive, rapid diagnostic testing, now being developed to fill an unmet need in the health care marketplace.
For other grant mechanisms, NIH may expect publications, graduate course and thesis completion, and training events or curricula to result from the grant, but SBIR is the only mechanism that “requires” post-funding actions. In addition to Phase 1 and Phase II, the SBIR program has built into the funding mechanism a Phase III for commercialization of the products developed in the earlier phases. SBIR grantees treat this third phase with widely divergent levels of enthusiasm and planned activity. It could be argued that Phase III, which includes no funding from NIH, is the most important phase. For SBIR to be successful, products with proven efficacy need to get out into market for public use. In this session, early-stage and longer-term Phase III SBIR grantees will share: a) the strategies and challenges faced in Phase III; b) lessons they have learned about starting early in planning for Phase III – what can be done in Phases I and II to increase the likelihood of Phase III success? and c) recommendations for new and experienced SBIR grantees in planning for Phase III.
Health disparities are not easily addressed, but SBIR grants can help tackle related economic and health care challenges. Dr. Hester will describe his experience in moving his academic findings in drug dependencies to a socially impactful internet-based business.
Tracking the Web: Using Interactive Media and IT for Health Care(Convener: Vincent Thomas, Moderator: Rohit Shukla, Speakers: Charles Lee and Bill Tan)
Web-based solutions, including mobile apps, e-health portals, point-of-care systems, training programs and software, are increasingly being developed and deployed to address “meaningful care” health care solutions. These products and services are positively influenced by outreach, education, reimbursement and patient-reported outcomes and have the potential to make health care more transparent and more engaging. Small businesses that are developing solutions in this area typify the commercialization challenges confronting innovators in a highly fragmented market. This panel will explore these challenges through the experiences of two successful company leaders. A moderator will introduce the issues, followed by comments and “tales from the trenches” from the two leaders. The panel will also include an opportunity for interactive discussion between panelists and the audience. How does one establish validation for one’s solutions in this new marketplace? What does “collaboration” look like? How does one accelerate the notoriously slow cycles in health care? What can a small business do to enhance its chances of a successful exit? These and other questions will be addressed in a dynamic exchange.
Did you know that NIH licenses inventions from NIH, FDA and CDC, has developed two exclusive licenses tailored for startup companies and offers SBIR- technology transfer grants and contracts, as well as conducts research collaborations with industry? Technology transfer is a bridge that connects inventive discoveries to commercial partners that develop these technologies into products and services. In order to meet industry needs, there are a variety of mechanisms available ranging from exclusive and non-exclusive licensing, cooperative research and development agreements, material transfer and clinical trial agreements, as well as SBIR-technology transfer grants and contracts. This bridge from bench to bedside makes it possible for the public to benefit from the full potential of biomedical inventions.
Description to come
Description to come
Description to come